van den Borne BE - Search Results

1

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.

van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. van den Borne BE, et al. J Rheumatol. 1997 Jan;24(1):55-60. J Rheumatol. 1997. PMID: 9002011

2

Combination cyclosporine and (hydroxy)chloroquine in rheumatoid arthritis.

Dijkmans BA, Landewé RB, van den Borne BE, Breedveld FC. Dijkmans BA, et al. Among authors: van den borne be. Clin Exp Rheumatol. 1999 Nov-Dec;17(6 Suppl 18):S103-4. Clin Exp Rheumatol. 1999. PMID: 10589367 Clinical Trial.

3

Chloroquine therapy in patients with recent-onset rheumatoid arthritis: the clinical response can be predicted by the low level of acute-phase reaction at baseline.

van den Borne BE, Landewé RB, Rietveld JH, Goei The HS, Griep EN, Breedveld FC, Dijkmans BA. van den Borne BE, et al. Clin Rheumatol. 1999;18(5):369-72. doi: 10.1007/s100670050121. Clin Rheumatol. 1999. PMID: 10524550 Clinical Trial.

4

Cyclosporin A therapy in rheumatoid arthritis: only strict application of the guidelines for safe use can prevent irreversible renal function loss.

van den Borne BE, Landewé RB, Goei The HS, Breedveld FC, Dijkmans BA. van den Borne BE, et al. Rheumatology (Oxford). 1999 Mar;38(3):254-9. doi: 10.1093/rheumatology/38.3.254. Rheumatology (Oxford). 1999. PMID: 10325664

5

No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.

van den Borne BE, Landewé RB, Houkes I, Schild F, van der Heyden PC, Hazes JM, Vandenbroucke JP, Zwinderman AH, Goei The HS, Breedveld FC, Bernelot Moens HJ, Kluin PM, Dijkmans BA. van den Borne BE, et al. Among authors: van der heyden pc. Arthritis Rheum. 1998 Nov;41(11):1930-7. doi: 10.1002/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N. Arthritis Rheum. 1998. PMID: 9811046

6

Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine.

van den Borne BE, Landewé RB, Goei The HS, Rietveld JH, Zwinderman AH, Bruyn GA, Breedveld FC, Dijkmans BA. van den Borne BE, et al. J Rheumatol. 1998 Aug;25(8):1493-8. J Rheumatol. 1998. PMID: 9712089 Clinical Trial.

7

Low dose cyclosporine in early rheumatoid arthritis: effective and safe after two years of therapy when compared with chloroquine.

van den Borne BE, Landewé RB, The HS, Breedveld FC, Dijkmans BA. van den Borne BE, et al. Scand J Rheumatol. 1996;25(5):307-16. doi: 10.3109/03009749609104063. Scand J Rheumatol. 1996. PMID: 8921924 Clinical Trial.

8

Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis.

van den Borne BE, Landewé RB, Goei The HS, Mattie H, Breedveld FC, Dijkmans BA. van den Borne BE, et al. Br J Clin Pharmacol. 1995 Feb;39(2):172-5. doi: 10.1111/j.1365-2125.1995.tb04425.x. Br J Clin Pharmacol. 1995. PMID: 7742156 Free PMC article. Clinical Trial.

9

Chloroquine combined with cyclosporine in rheumatoid arthritis: more than the addition of 2 drugs alone.

Dijkmans BA, van den Borne BE, Landewe RB, Miltenburg AM, Verweij CL, Breedveld FC. Dijkmans BA, et al. Among authors: van den borne be. J Rheumatol Suppl. 1996 Mar;44:61-3. J Rheumatol Suppl. 1996. PMID: 8833055 Review.

10

Androgenizing effects of low-dose cyclosporin in male patients with early RA.

Giltay EJ, van den Borne BE, van Schaardenburg D, Gooren LJ, Popp-Snijders C, Blankenstein MA, Dijkmans BA. Giltay EJ, et al. Among authors: van den borne be, van schaardenburg d. Br J Rheumatol. 1998 Apr;37(4):470-2. doi: 10.1093/rheumatology/37.4.470. Br J Rheumatol. 1998. PMID: 9619909 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results